Kite
Apr 23, 2020
AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes
AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
